Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Income from Continuing Operations for 6 consecutive years, with 14571000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 79.25% year-over-year to 14571000.0, compared with a TTM value of 75946000.0 through Sep 2025, down 31.21%, and an annual FY2024 reading of 61183000.0, up 16.7% over the prior year.
  • Income from Continuing Operations was 14571000.0 for Q3 2025 at Barinthus Biotherapeutics, up from 21126000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15689000.0 in Q2 2022 and bottomed at 23824000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 12197941.18, with a median of 16837000.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations soared 261.58% in 2022, then tumbled 1294.17% in 2023.
  • Year by year, Income from Continuing Operations stood at 16837000.0 in 2021, then dropped by 25.69% to 21163000.0 in 2022, then rose by 18.3% to 17290000.0 in 2023, then dropped by 19.09% to 20591000.0 in 2024, then grew by 29.24% to 14571000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BRNS at 14571000.0 in Q3 2025, 21126000.0 in Q2 2025, and 19658000.0 in Q1 2025.